

## Living Cell Technologies Limited

**ABN:** 14 104 028 042  
**ASX:** LCT  
**OTCQB:** LVCLY

09 June 2023

Living Cell Technologies Limited  
Level 23, Rialto South Tower  
525 Collins Street  
Melbourne, Victoria 3000  
AUSTRALIA  
Ph: +61 422 180 317  
Email: [brad@lctglobal.com](mailto:brad@lctglobal.com)  
Web: [www.lctglobal.com](http://www.lctglobal.com)  
ABN: 14 104 028 042

## Appointment of Chief Scientific Officer – Dr James Mckenna

Melbourne, Australia, 09 June 2023 - Living Cell Technologies Limited (ASX: LCT) (OTC: LVCLY) (“LCT” or “the Company”) is delighted to announce the appointment of Dr James A Mckenna as Chief Scientific Officer (‘CSO’) of the Company. Dr Mckenna is an experienced research scientist who holds a PhD in biochemistry and molecular biology from the University of Melbourne.

Dr Mckenna has been a full-time research scientist for 23 years, with experience in academic science, commercial drug development and intellectual property generation. Most recently, he held a leadership position at an ASX listed biotechnology company where he managed and was involved in teams to advance pre-clinical and clinical research and development (R&D) programs for the purpose of achieving US Food and Drug Administration (FDA) registration.

Dr Mckenna’s appointment coincides with LCT’s corporate strategy to expand and diversify the Company’s development pipeline. The role of CSO will include:

- research pertaining to drug candidate development,
- arrangement of pre-clinical and clinical studies, and
- liaison with intellectual property attorneys and pharmaceutical regulators.

LCT has multiple projects and drug candidates under scientific assessment and has entered discussions with contract research organisations and academic institutions to assist in the origination of additional projects. Any formal appointments of such organisations will coincide with the commencement of one or more additional projects. The Director’s will update the market upon that occurrence. The Company will seek to re-name and rebrand LCT in due course to reflect a diversified product pipeline.

Dr Mckenna commences the role of CSO on 19 June 2023.

**This announcement has been approved for release to ASX by the LCT Board of Directors.**

**END**

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

**Corporate and Media Enquiries**

Brad Dilkes  
Non-executive Director  
Mobile: +61 422 180 317  
[brad@lctglobal.com](mailto:brad@lctglobal.com)

**About Living Cell Technologies**

Living Cell Technologies Limited is a biotechnology company focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease. The Company is incorporated in Australia, with its operations based in Australia and New Zealand. LCT is listed on Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter, Facebook or LinkedIn.

**Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.